EULAV Asset Management Boosts Position in Intercept Pharmaceuticals, Inc. (ICPT)

EULAV Asset Management boosted its stake in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) by 17.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,000 shares of the biopharmaceutical company’s stock after buying an additional 7,000 shares during the period. EULAV Asset Management owned about 0.19% of Intercept Pharmaceuticals worth $7,571,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. KBC Group NV increased its position in Intercept Pharmaceuticals by 660.2% in the third quarter. KBC Group NV now owns 897 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 779 shares in the last quarter. Legal & General Group Plc increased its position in Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 52 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its position in Intercept Pharmaceuticals by 3.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 1,234 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 38 shares in the last quarter. Pacer Advisors Inc. purchased a new position in Intercept Pharmaceuticals during the second quarter valued at $180,000. Finally, IBM Retirement Fund increased its position in Intercept Pharmaceuticals by 3.6% in the second quarter. IBM Retirement Fund now owns 1,657 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 58 shares in the last quarter. 82.40% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) traded up 1.19% during midday trading on Wednesday, reaching $106.92. The company’s stock had a trading volume of 356,643 shares. The firm’s market capitalization is $2.65 billion. Intercept Pharmaceuticals, Inc. has a 1-year low of $89.76 and a 1-year high of $177.93. The company’s 50-day moving average price is $107.02 and its 200 day moving average price is $137.97.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.82) by $0.23. Intercept Pharmaceuticals had a negative return on equity of 66.97% and a negative net margin of 3,287.95%. The business earned $4.70 million during the quarter, compared to analyst estimates of $4.77 million. During the same quarter last year, the firm earned ($2.10) earnings per share. The company’s revenue for the quarter was up 1051.1% compared to the same quarter last year. On average, equities research analysts forecast that Intercept Pharmaceuticals, Inc. will post ($15.64) earnings per share for the current year.

WARNING: This piece was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2017/01/11/eulav-asset-management-boosts-position-in-intercept-pharmaceuticals-inc-icpt.html.

Several research firms have weighed in on ICPT. JMP Securities reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Sunday, November 6th. Robert W. Baird reaffirmed an “outperform” rating and issued a $332.00 target price on shares of Intercept Pharmaceuticals in a research report on Monday, November 7th. Wedbush reissued an “outperform” rating and set a $224.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, December 30th. FBR & Co reissued a “neutral” rating on shares of Intercept Pharmaceuticals in a research report on Friday, November 18th. Finally, Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $200.00 price objective (down from $250.00) on shares of Intercept Pharmaceuticals in a research report on Monday, October 24th. Four analysts have rated the stock with a sell rating, four have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $181.48.

In other Intercept Pharmaceuticals news, CMO David Shapiro sold 988 shares of the firm’s stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $103.92, for a total transaction of $102,672.96. Following the completion of the sale, the chief marketing officer now owns 41,934 shares in the company, valued at approximately $4,357,781.28. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Rachel Mcminn sold 816 shares of the firm’s stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $103.92, for a total value of $84,798.72. Following the sale, the insider now owns 12,916 shares of the company’s stock, valued at approximately $1,342,230.72. The disclosure for this sale can be found here. 9.20% of the stock is owned by insiders.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

What are top analysts saying about Intercept Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intercept Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit